US Press Releases

Oncopeptides’ PEPAXTO® Receives a Permanent J-Code, Clarifying Reimbursement Processes in Hospital Outpatient and Physician Office Settings of Care

August 16, 2021

BOSTON— August 16, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announc...

Read more

Oncopeptides’ PEPAXTO ® Receives a Specific C-Code and Pass-Through Payment Status Further Streamlining Reimbursement in Hospital Sites of Care

July 13, 2021

BOSTON— July 13, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced...

Read more

Oncopeptides shares updated results from the phase 3 OCEAN study based upon further analysis

July 8, 2021

--

Read more

Phase 3 OCEAN study demonstrates that melphalan flufenamide is at least as efficacious as pomalidomide, the most used medicine in relapsed refractory multiple myeloma

May 26, 2021

--

Read more

Oncopeptides announces three abstracts accepted by the 2021 American Society of Clinical Oncology

May 19, 2021

WALTHAM — May 19, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announce...

Read more

Oncopeptides Completes Patient Enrollment in Phase 2 PORT Study

May 5, 2021

WALTHAM —May 5, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced ...

Read more

Oncopeptides Announces National Comprehensive Cancer Network® Adds PEPAXTO® (melphalan flufenamide) to Its Multiple Myeloma Clinical Practice Guidelines

March 22, 2021

--

Read more

Oncopeptides Announces Commercial Availability of PEPAXTO® (melphalan flufenamide)

March 15, 2021

--

Read more

Read the press release on the FDA approval of PEPAXTO

March 1, 2021

-

Read more